DOCSLIB.ORG

Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride S Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2016/05/18/mol.115.102731.DC1 1521-0111/90/2/80–95$25.00 http://dx.doi.org/10.1124/mol.115.102731 MOLECULAR PHARMACOLOGY Mol Pharmacol 90:80–95, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride s Pouria H. Jalily, Jodene Eldstrom, Scott C. Miller, Daniel C. Kwan, Sheldon S. -H. Tai, Doug Chou, Masahiro Niikura, Ian Tietjen, and David Fedida Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver (P.H.J., J.E., S.C.M., D.C.K., D.C., I.T., D.F.), and Faculty of Health Sciences, Simon Fraser University, Burnaby (S.S.-H.T., M.N., I.T.), British Columbia, Canada Received December 7, 2015; accepted May 12, 2016 Downloaded from ABSTRACT The increasing prevalence of influenza viruses with resistance to [1,19-biphenyl]-4-carboxylate (27) acts both on adamantane- approved antivirals highlights the need for new anti-influenza sensitive and a resistant M2 variant encoding a serine to asparagine therapeutics. Here we describe the functional properties of hexam- 31 mutation (S31N) with improved efficacy over amantadine and – 5 m m ethylene amiloride (HMA) derived compounds that inhibit the wild- HMA (IC50 0.6 Mand4.4 M, respectively). Whereas 9 inhibited molpharm.aspetjournals.org type and adamantane-resistant forms of the influenza A M2 ion in vitro replication of influenza virus encoding wild-type M2 (EC50 5 channel. For example, 6-(azepan-1-yl)-N-carbamimidoylnicotina- 2.3 mM), both 27 and tert-butyl 49-(carbamimidoylcarbamoyl)-29,3- mide (9) inhibits amantadine-sensitive M2 currents with 3- to dinitro-[1,19-biphenyl]-4-carboxylate (26) preferentially inhibited 6-fold greater potency than amantadine or HMA (IC50 5 0.2 vs. viruses encoding M2(S31N) (respective EC50 5 18.0 and 1.5 mM). 0.6 and 1.3 mM, respectively). Compound 9 competes with This finding indicates that HMA derivatives can be designed to inhibit amantadine for M2 inhibition, and molecular docking simulations viruses with resistance to amantadine. Our study highlights the suggest that 9 binds at site(s) that overlap with amantadine binding. potential of HMA derivatives as inhibitors of drug-resistant influenza In addition, tert-butyl 49-(carbamimidoylcarbamoyl)-29,3-dinitro- M2 ion channels. at ASPET Journals on October 2, 2021 Introduction is proton-gated and proton-selective (Nieva et al., 2012). After viral entry into host cells, M2 conducts protons from acidic Viroporins are virally encoded transmembrane proteins that host-cell endosomes to the virion interior to allow for uncoating facilitate conduction of ions or small molecules and are and release of viral RNA. M2 on host-cell endosomal mem- required for efficient viral replication (Nieva et al., 2012). branes is also observed in some cases to conduct protons Despite their small size (frequently ,100 amino acids), to elevate secretory vesicle pH, thereby delaying egress of viroporins in many cases have evolved to function as highly nascent virion particles and preventing viral hemagglutinin regulated ion channels, which makes them attractive mini- from adopting a nonfunctional, low pH conformation (Sugrue malist models of ion conductance and ion channel evolution et al., 1990; Alvarado-Facundo et al., 2015). The M2 ion (Pinto et al., 1992; Stouffer et al., 2008; Thiel et al., 2011; channel of influenza B (B/M2) is a functional homolog of OuYang et al., 2013; OuYang and Chou, 2014). The M2 A/M2. It is 109 residues long and forms a homotetramer in viroporin of influenza A is a 97-amino-acid, type I transmem- the membrane like A/M2. Furthermore, B/M2 exhibits higher brane domain protein that forms a tetrameric ion channel that channel activity but shows a similar pH dependence in terms of its proton conductance; however, major differences exist be- This work was funded by a Canadian Institutes of Health Research tween the two channels. Other than the HXXXW sequence Industry-Partnered Collaborative Research Operating Grant [IPR-124291] motif crucial for channel activity, the two proteins share nearly which was cofunded by Cardiome Pharma Corp., Vancouver, Canada. We also no sequence homology, and unlike A/M2, the B/M2 proton wish to acknowledge the support from Grand Challenges Canada [0487-01-10]. Grand Challenges Canada is funded by the Government of Canada and is conductance activity is entirely insensitive to amantadine and dedicated to supporting Bold Ideas with Big Impact in global health. rimantadine (Mould et al., 2003; Wang et al., 2009). dx.doi.org/10.1124/mol.115.102731. s This article has supplemental material available at molpharm. The compounds amantadine and rimantadine (Fig. 1A) are aspetjournals.org. potent inhibitors of A/M2 proton conductance and licensed ABBREVIATIONS: B/M2, M2 ion channel of influenza B; Boc, tert-butyloxycarbonyl; BIT-225, N-(5-(1-methyl-1H-pyrazol-4-yl)naphthalene-2- carbonyl)guanidine; EIPA, 5-(N-ethyl-N-isopropyl)-amiloride; GFP, green fluorescent protein; HMA, hexamethylene amiloride; I-V, current-voltage relationship; IC50, half-maximal inhibitory concentration; LM, ltk- murine fibroblast; MDCK, Madin-Darby canine kidney cell line; MEM, modified Eagle’s medium; MES, 4-morpholineethanesulfonic acid; M2WJ352, N-((5-(thiophen-2-yl)isoxazol-3-yl)methyl)adamantan-1-amine; M2WJ332, N- ((5-(thiophen-2-yl)isoxazol-3-yl)methyl)adamantan-1-amine; NMDG, N-methyl-D-glucamine; NMR, nuclear magnetic resonance; N31, asparagine at position 31; PCR, polymerase chain reaction; pHi, internal solution pH; pHo, external solution pH; RMSD, root mean square deviation; SAR, structure-activity relationship; SARS-COV, severe acute respiratory syndrome coronavirus; S31, serine at position 31; TEVC, two-electrode voltage clamp; T27, threonine at position 27; V27, valine at position 27; WT, wild type. 80 Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors 81 as potassium-sparing diuretics, acylguanidine-containing amilorides, and hexamethylene amiloride (HMA) in particular (Fig. 1B), are inhibitors of multiple viroporins including those of hepatitis virus, HIV-1, and severe acute respiratory syn- drome coronavirus (SARS-CoV) (Kleyman and Cragoe, 1988; Ewart et al., 2002; Premkumar et al., 2004; Pervushin et al., 2009; Gazina and Petrou, 2012). HMA has also been report- ed to inhibit M2(WT) (IC50 5 1.1 mM by TEVC) but not M2(S31N), whereas a related compound N-(5-(1-methyl-1H- pyrazol-4-yl)naphthalene-2-carbonyl)guanidine (BIT-225; Fig. 1B) inhibits currents from the viroporins of hepatitis C and HIV-1 and shows promising activity in early clinical trials (Khoury et al., 2010; Luscombe et al., 2010; Gazina and Petrou, 2012). Although additional acylguanidines, including ethyl-isopropyl amiloride (EIPA) and (6-(1-methylpryazol- 4-yl)-2-napthoyl)guanidinium (BIT-314; Fig. 1B), are also reported to have antiviral activity against multiple viroporins Downloaded from and viruses, their effects on M2 currents are not yet reported (Ewart et al., 2009; Gazina and Petrou, 2012). Herein we describe an electrophysiology-driven approach to characterize the mechanism of and pharmacologically evaluate a series of acylguanidines and HMA-like derivatives on inhibition of WT and adamantane-resistant influenza M2 viroporins. molpharm.aspetjournals.org Fig. 1. Examples of reported M2 inhibitors. (A) Adamantane inhibitors: amantadine, rimantadine, and N-((5-(thiophen-2-yl)isoxazol-3-yl)methyl)- Materials and Methods adamantan-1-amine (M2WJ352) (Wang et al., 2013b). (B) Acylguanidines: HMA (Gazina and Petrou, 2012), BIT-225 (Khoury et al., 2010; Luscombe Chemistry. Detailed information for the synthesis and character- et al., 2010), EIPA, and BIT-314. ization of compounds 1–33 can be found in the Supplemental Material. M2WJ352 was synthesized as described previously (Wang et al., 2013b). Amantadine hydrochloride, 5-(N,N-hexamethylene)amiloride, influenza antivirals (Hay et al., 1985; Pinto et al., 1992; 5-(N-ethyl-N-isopropyl)amiloride, and 1-benzoylguanidine were pur- Chizhmakov et al., 1996); however, M2 sequence changes that chased from Sigma-Aldrich (St. Louis, MO). render resistance to adamantanes are now so prevalent that Electrophysiology. The tsA-201 cells, a derivative of the HEK at ASPET Journals on October 2, 2021 these compounds are no longer recommended for use (Fiore 293T cell line, or ltk- murine fibroblast (LM) cells were cultured in et al., 2011). For example, more than 90% of transmissible modified Eagle’s medium plus 10% fetal calf serum, 100 U/ml m 1 adamantane-resistant influenza strains encode an M2 serine penicillin, and 100 g/ml streptomycin (MEM medium). cDNA sequences encoding full-length M2 were derived from the A/Hong to asparagine mutation at position 31 (S31N). This mutation Kong/1073/99(H9N2) or B/Lee/1940 references sequence and con- disrupts adamantane interactions within the M2 pore without tained an N-terminal FLAG-tag plus 3 (Gly) repeat linker. This tag adversely affecting ion channel activity (Hay et al., 1986; was used to confirm M2(WT) expression on the cell surface of Belshe et al., 1988; Pinto et al., 1992; Bright et al., 2005; transfected cells by immunocytochemistry (Supplemental Fig. 1). Stouffer et al., 2008; Balannik et al., 2010). Thus, new small M2 sequences were cloned into the pcDNA3 plasmid and tran- molecules that inhibit adamantane-resistant M2 are needed siently cotransfected with a pcDNA3 plasmid encoding green for both improved understanding of the chemical space and fluorescent protein (GFP) into tsA-201 cells using standard trans- mechanisms by which M2 activity can be modified in addition fection protocols (Lipofectamine 2000; Life Technologies, Waltham, to development of new influenza antivirals. MA); 24–48 hours after transfection, single GFP-positive cells were – To date, few compounds are reported to act on the S31N perfused continuously at 3 5 ml/min with external (bath) solution containing (in mM): 150 NMDG, 10 HEPES, 10 D-glucose, 2 CaCl , form of M2 from influenza A.
Load more

Recommended publications
  • A Small Molecule Compound IMB-LA Inhibits HIV-1 Infection By
    www.nature.com/scientificreports OPEN A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from Received: 18 May 2015 Accepted: 19 November 2015 antagonizing the host restriction Published: 16 December 2015 factor BST-2 Zeyun Mi1,5,*, Jiwei Ding1,*, Quan Zhang1,*, Jianyuan Zhao2, Ling Ma1, Haisheng Yu6, Zhenlong Liu3, Guangzhi Shan1, Xiaoyu Li1, Jinming Zhou1, Tao Wei2, Liguo Zhang6, Fei Guo4, Chen Liang3 & Shan Cen1 Human BST-2 inhibits HIV-1 replication by tethering nascent virions to the cell surface. HIV-1 codes Vpu that counteracts BST-2 by down-regulating this restriction factor from the cell surface. This important function makes Vpu a potential therapeutic target. Yet, no agents have been reported to block Vpu from antagonizing BST-2. In this study, we report a small molecule compound IMB-LA that abrogates the function of Vpu and thereby strongly suppresses HIV-1 replication by sensitizing the virus to BST-2 restriction. Further studies revealed that IMB-LA specifically inhibits Vpu-mediated degradation of BST-2 and restores the expression of BST-2 at the cell surface. Although IMB-LA does not prevent Vpu from interacting with BST-2 or β-TrCP2-containing ubiquitin E3 ligase, sorting of BST-2 into lysosomes in Vpu-expressing cells is blocked by IMB-LA. Most importantly, HIV-1 release and infection is inhibited by IMB-LA only in BST-2-expressing cells. In summary, results herein demonstrated that IMB-LA could specifically inhibit the degradation of BST-2 induced by Vpu, and impair HIV-1 replication in a BST-2 dependent manner, suggesting the feasibility of utilizing small molecule compounds to disable the antagonist function of Vpu and thereby expose HIV-1 to the restriction by BST-2.
    [Show full text]
  • Type of the Paper (Article
    Viruses 2018 – Breakthroughs in Viral Replication Faculty of Biology University of Barcelona Spain 7 – 9 February 2018 Conference Chair Eric O. Freed Conference Co-Chair Albert Bosch Organised by Conference Secretariat Antonio Peteira Man Luo George Andrianou Nikoleta Kiapidou Kristjana Xhuxhi Pablo Velázquez Lucia Russo Sara Martínez Lynn Huang Sarai Rodríguez Viruses 2018 – Breakthroughs in Viral Replication 1 CONTENTS Abridged Programme 5 Conference Programme 6 Welcome 13 General Information 15 Abstracts – Session 1 25 General Topics in Virology Abstracts – Session 2 45 Structural Virology Abstracts – Session 3 67 Virus Replication Compartments Abstracts – Session 4 89 Replication and Pathogenesis of RNA viruses Abstracts – Session 5 105 Genome Packaging and Replication/Assembly Abstracts – Session 6 127 Antiviral Innate Immunity and Viral Pathogenesis Abstracts – Poster Exhibition 147 List of Participants 297 Viruses 2018 – Breakthroughs in Viral Replication 3 Viruses 2018 – Breakthroughs in Viral Replication 7 – 9 February 2018, Barcelona, Spain Wednesday Thursday Friday 7 February 2018 8 February 2018 9 February 2018 S3. Virus S5. Genome Check-in Replication Packaging and Compartments Replication/Assembly Opening Ceremony S1. General Topics in Virology Morning Coffee Break S1. General Topics S3. Virus S5. Genome in Virology Replication Packaging and Compartments Replication/Assembly Lunch S2. Structural S4. Replication and S6. Antiviral Innate Virology Pathogenesis of Immunity and Viral RNA Viruses Pathogenesis Coffee Break Apéro and Poster Coffee Break Session S2. Structural S6. Antiviral Innate Virology Immunity and Viral Afternoon Conference Group Pathogenesis Photograph Closing Remarks Conference Dinner Wednesday 7 February 2018: 08:00 - 12:30 / 14:00 - 18:00 / Conference Dinner: 20:30 Thursday 8 February 2018: 08:30 - 12:30 / 14:00 - 18:30 Friday 9 February 2018: 08:30 - 12:30 / 14:00 - 18:15 Viruses 2018 – Breakthroughs in Viral Replication 5 Conference Programme Wednesday 7 February 08:00 – 08:45 Check-in 08:45 – 09:00 Opening Ceremony by Eric O.
    [Show full text]
  • HIV-1 Rev Downregulates Tat Expression and Viral Replication Via Modulation of NAD(P)H:Quinine Oxidoreductase 1 (NQO1)
    ARTICLE Received 25 Jul 2014 | Accepted 22 Apr 2015 | Published 10 Jun 2015 DOI: 10.1038/ncomms8244 HIV-1 Rev downregulates Tat expression and viral replication via modulation of NAD(P)H:quinine oxidoreductase 1 (NQO1) Sneh Lata1,*, Amjad Ali2,*, Vikas Sood1,2,w, Rameez Raja2 & Akhil C. Banerjea2 HIV-1 gene expression and replication largely depend on the regulatory proteins Tat and Rev, but it is unclear how the intracellular levels of these viral proteins are regulated after infection. Here we report that HIV-1 Rev causes specific degradation of cytoplasmic Tat, which results in inhibition of HIV-1 replication. The nuclear export signal (NES) region of Rev is crucial for this activity but is not involved in direct interactions with Tat. Rev reduces the levels of ubiquitinated forms of Tat, which have previously been reported to be important for its transcriptional properties. Tat is stabilized in the presence of NAD(P)H:quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor. Furthermore, Rev causes specific reduction in the levels of endogenous NQO1. Thus, we propose that Rev is able to induce degradation of Tat indirectly by downregulating NQO1 levels. Our findings have implications in HIV-1 gene expression and latency. 1 Department of Microbiology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi 110095, India. 2 Laboratory of Virology, National Institute of Immunology, New Delhi 110067, India. * These authors contributed equally to this work. w Present address: Translational Health Science and Technology Institute, Faridabad, Haryana 121004, India. Correspondence and requests for materials should be addressed to A.C.B.
    [Show full text]
  • A SARS-Cov-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
    A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing Supplementary Information Supplementary Discussion All SARS-CoV-2 protein and gene functions described in the subnetwork appendices, including the text below and the text found in the individual bait subnetworks, are based on the functions of homologous genes from other coronavirus species. These are mainly from SARS-CoV and MERS-CoV, but when available and applicable other related viruses were used to provide insight into function. The SARS-CoV-2 proteins and genes listed here were designed and researched based on the gene alignments provided by Chan et. al. 1 2020 .​ Though we are reasonably sure the genes here are well annotated, we want to note that not every ​ protein has been verified to be expressed or functional during SARS-CoV-2 infections, either in vitro or in vivo. ​ ​ In an effort to be as comprehensive and transparent as possible, we are reporting the sub-networks of these functionally unverified proteins along with the other SARS-CoV-2 proteins. In such cases, we have made notes within the text below, and on the corresponding subnetwork figures, and would advise that more caution be taken when examining these proteins and their molecular interactions. Due to practical limits in our sample preparation and data collection process, we were unable to generate data for proteins corresponding to Nsp3, Orf7b, and Nsp16. Therefore these three genes have been left out of the following literature review of the SARS-CoV-2 proteins and the protein-protein interactions (PPIs) identified in this study.
    [Show full text]
  • Symposium on Viral Membrane Proteins
    Viral Membrane Proteins ‐ Shanghai 2011 交叉学科论坛 Symposium for Advanced Studies 第二十七期：病毒离子通道蛋白的结构与功能研讨会 Symposium on Viral Membrane Proteins 主办单位：中国科学院上海交叉学科研究中心 承办单位：上海巴斯德研究所 1 Viral Membrane Proteins ‐ Shanghai 2011 Symposium on Viral Membrane Proteins Shanghai Institute for Advanced Studies, CAS Institut Pasteur of Shanghai,CAS 30.11. – 2.12 2011 Shanghai, China 2 Viral Membrane Proteins ‐ Shanghai 2011 Schedule: Wednesday, 30th of November 2011 Morning Arrival Thursday, 1st of December 2011 8:00 Arrival 9:00 Welcome Bing Sun, Co-Director, Pasteur Institute Shanghai 9: 10 – 9:35 Bing Sun, Pasteur Institute Shanghai Ion channel study and drug target fuction research of coronavirus 3a like protein. 9:35 – 10:00 Tim Cross, Tallahassee, USA The proton conducting mechanism and structure of M2 proton channel in lipid bilayers. 10:00 – 10:25 Shy Arkin, Jerusalem, IL A backbone structure of SARS Coronavirus E protein based on Isotope edited FTIR, X-ray reflectivity and biochemical analysis. 10:20 – 10:45 Coffee Break 10:45 – 11:10 Rainer Fink, Heidelberg, DE Elektromechanical coupling in muscle: a viral target? 11:10 – 11:35 Yechiel Shai, Rehovot, IL The interplay between HIV1 fusion peptide, the transmembrane domain and the T-cell receptor in immunosuppression. 11:35 – 12:00 Christoph Cremer, Mainz and Heidelberg University, DE Super-resolution Fluorescence imaging of cellular and viral nanostructures. 12:00 – 13:30 Lunch Break 3 Viral Membrane Proteins ‐ Shanghai 2011 13:30 – 13:55 Jung-Hsin Lin, National Taiwan University Robust Scoring Functions for Protein-Ligand Interactions with Quantum Chemical Charge Models. 13:55 – 14:20 Martin Ulmschneider, Irvine, USA Towards in-silico assembly of viral channels: the trials and tribulations of Influenza M2 tetramerization.
    [Show full text]
  • Viroporins: Structures and Functions Beyond Cell Membrane Permeabilization
    Editorial Viroporins: Structures and Functions beyond Cell Membrane Permeabilization José Luis Nieva 1,* and Luis Carrasco 2,* Received: 17 September 2015 ; Accepted: 21 September 2015 ; Published: 29 September 2015 Academic Editor: Eric O. Freed 1 Biophysics Unit (CSIC, UPV/EHU) and Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080 Bilbao, Spain 2 Centro de Biología Molecular Severo Ochoa (CSIC, UAM), c/Nicolás Cabrera, 1, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain * Correspondence: [email protected] (J.L.N.); [email protected] (L.C.); Tel.: +34-94-601-3353 (J.L.N.); +34-91-497-8450 (L.C.) Viroporins represent an interesting group of viral proteins that exhibit two sets of functions. First, they participate in several viral processes that are necessary for efficient production of virus progeny. Besides, viroporins interfere with a number of cellular functions, thus contributing to viral cytopathogenicity. Twenty years have elapsed from the first review on viroporins [1]; since then several reviews have covered the advances on viroporin structure and functioning [2–8]. This Special Issue updates and revises new emerging roles of viroporins, highlighting their potential use as antiviral targets and in vaccine development. Viroporin structure. Viroporins are usually short proteins with at least one hydrophobic amphipathic helix. Homo-oligomerization is achieved by helix–helix interactions in membranes rendering higher order structures, forming aqueous pores. Progress in viroporin structures during the last 2–3 years has in some instances provided a detailed knowledge of their functional architecture, including the fine definition of binding sites for effective inhibitors.
    [Show full text]
  • How Influenza Virus Uses Host Cell Pathways During Uncoating
    cells Review How Influenza Virus Uses Host Cell Pathways during Uncoating Etori Aguiar Moreira 1 , Yohei Yamauchi 2 and Patrick Matthias 1,3,* 1 Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland; [email protected] 2 Faculty of Life Sciences, School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK; [email protected] 3 Faculty of Sciences, University of Basel, 4031 Basel, Switzerland * Correspondence: [email protected] Abstract: Influenza is a zoonotic respiratory disease of major public health interest due to its pan- demic potential, and a threat to animals and the human population. The influenza A virus genome consists of eight single-stranded RNA segments sequestered within a protein capsid and a lipid bilayer envelope. During host cell entry, cellular cues contribute to viral conformational changes that promote critical events such as fusion with late endosomes, capsid uncoating and viral genome release into the cytosol. In this focused review, we concisely describe the virus infection cycle and highlight the recent findings of host cell pathways and cytosolic proteins that assist influenza uncoating during host cell entry. Keywords: influenza; capsid uncoating; HDAC6; ubiquitin; EPS8; TNPO1; pandemic; M1; virus– host interaction Citation: Moreira, E.A.; Yamauchi, Y.; Matthias, P. How Influenza Virus Uses Host Cell Pathways during 1. Introduction Uncoating. Cells 2021, 10, 1722. Viruses are microscopic parasites that, unable to self-replicate, subvert a host cell https://doi.org/10.3390/ for their replication and propagation. Despite their apparent simplicity, they can cause cells10071722 severe diseases and even pose pandemic threats [1–3].
    [Show full text]
  • Opportunistic Intruders: How Viruses Orchestrate ER Functions to Infect Cells
    REVIEWS Opportunistic intruders: how viruses orchestrate ER functions to infect cells Madhu Sudhan Ravindran*, Parikshit Bagchi*, Corey Nathaniel Cunningham and Billy Tsai Abstract | Viruses subvert the functions of their host cells to replicate and form new viral progeny. The endoplasmic reticulum (ER) has been identified as a central organelle that governs the intracellular interplay between viruses and hosts. In this Review, we analyse how viruses from vastly different families converge on this unique intracellular organelle during infection, co‑opting some of the endogenous functions of the ER to promote distinct steps of the viral life cycle from entry and replication to assembly and egress. The ER can act as the common denominator during infection for diverse virus families, thereby providing a shared principle that underlies the apparent complexity of relationships between viruses and host cells. As a plethora of information illuminating the molecular and cellular basis of virus–ER interactions has become available, these insights may lead to the development of crucial therapeutic agents. Morphogenesis Viruses have evolved sophisticated strategies to establish The ER is a membranous system consisting of the The process by which a virus infection. Some viruses bind to cellular receptors and outer nuclear envelope that is contiguous with an intri‑ particle changes its shape and initiate entry, whereas others hijack cellular factors that cate network of tubules and sheets1, which are shaped by structure. disassemble the virus particle to facilitate entry. After resident factors in the ER2–4. The morphology of the ER SEC61 translocation delivering the viral genetic material into the host cell and is highly dynamic and experiences constant structural channel the translation of the viral genes, the resulting proteins rearrangements, enabling the ER to carry out a myriad An endoplasmic reticulum either become part of a new virus particle (or particles) of functions5.
    [Show full text]
  • NSP4)-Induced Intrinsic Apoptosis
    viruses Article Viperin, an IFN-Stimulated Protein, Delays Rotavirus Release by Inhibiting Non-Structural Protein 4 (NSP4)-Induced Intrinsic Apoptosis Rakesh Sarkar †, Satabdi Nandi †, Mahadeb Lo, Animesh Gope and Mamta Chawla-Sarkar * Division of Virology, National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road Scheme-XM, Beliaghata, Kolkata 700010, India; [email protected] (R.S.); [email protected] (S.N.); [email protected] (M.L.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +91-33-2353-7470; Fax: +91-33-2370-5066 † These authors contributed equally to this work. Abstract: Viral infections lead to expeditious activation of the host’s innate immune responses, most importantly the interferon (IFN) response, which manifests a network of interferon-stimulated genes (ISGs) that constrain escalating virus replication by fashioning an ill-disposed environment. Interestingly, most viruses, including rotavirus, have evolved numerous strategies to evade or subvert host immune responses to establish successful infection. Several studies have documented the induction of ISGs during rotavirus infection. In this study, we evaluated the induction and antiviral potential of viperin, an ISG, during rotavirus infection. We observed that rotavirus infection, in a stain independent manner, resulted in progressive upregulation of viperin at increasing time points post-infection. Knockdown of viperin had no significant consequence on the production of total Citation: Sarkar, R.; Nandi, S.; Lo, infectious virus particles. Interestingly, substantial escalation in progeny virus release was observed M.; Gope, A.; Chawla-Sarkar, M. upon viperin knockdown, suggesting the antagonistic role of viperin in rotavirus release. Subsequent Viperin, an IFN-Stimulated Protein, studies unveiled that RV-NSP4 triggered relocalization of viperin from the ER, the normal residence Delays Rotavirus Release by Inhibiting of viperin, to mitochondria during infection.
    [Show full text]
  • Human Retroviruses in the Second Decade: a Personal Perspective
    © 1995 Nature Publishing Group http://www.nature.com/naturemedicine • REVIEW Human retroviruses in the second decade: A personal perspective Human retroviruses have developed novel strategies for their propagation and survival. A consequence of their success has been the induction of an extraordinarily diverse set of human dlst!ases, including AIDS, cancers and neurological and Inflammatory disorders. Early research focused on their characterization, linkage to these dlst!ases, and the mechanisms Involved. Research should now aim at the eradication of human retroviruses and on treatment of infected people. Retroviruses are transmitted either geneti- .................... ···.. .... ·. ..... .. discovered". Though its characteristics are cally (endogenous form) or as infectious ROBERT C. GALLO strikingly similar to HTLV-1, HTLV-II is not agents (exogenous form)'·'. As do many so clearly linked to human disease. It is cu­ other animal species, humans have both forms ..... In general, rious that HTLV-11 is endemic in some American Indians and endogenous retroviruses are evolutionary relics of old infec­ more prevalent in drug addicts than HTLV-I"·'•. tions and are not known to cause disease. The DNA of many HIV-1 is also most prevalent in equatorial Africa, but in con­ species, including humans, harbours multiple copies of differ­ trast to HTLV the demography of the HIV epidemic is still in ent retroviral proviruses. The human endogenous proviral flux, and the virus is new to most of the world. The number of sequences are virtually all defective, and comprise about one infected people worldwide is now estimated to be about 17 mil­ percent of the human genome, though R. Kurth's group in lion and is predicted to reach 30 to SO million by the year 2000.
    [Show full text]
  • Hepatitis C Virus P7—A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy
    Viruses 2010, 2, 2078-2095; doi:10.3390/v2092078 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Hepatitis C Virus P7—A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy Eike Steinmann and Thomas Pietschmann * TWINCORE †, Division of Experimental Virology, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625 Hannover, Germany; E-Mail: [email protected] † TWINCORE is a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI). * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-511-220027-130; Fax: +49-511-220027-139. Received: 22 July 2010; in revised form: 2 September 2010 / Accepted: 6 September 2010 / Published: 27 September 2010 Abstract: The hepatitis C virus (HCV), a hepatotropic plus-strand RNA virus of the family Flaviviridae, encodes a set of 10 viral proteins. These viral factors act in concert with host proteins to mediate virus entry, and to coordinate RNA replication and virus production. Recent evidence has highlighted the complexity of HCV assembly, which not only involves viral structural proteins but also relies on host factors important for lipoprotein synthesis, and a number of viral assembly co-factors. The latter include the integral membrane protein p7, which oligomerizes and forms cation-selective pores. Based on these properties, p7 was included into the family of viroporins comprising viral proteins from multiple virus families which share the ability to manipulate membrane permeability for ions and to facilitate virus production. Although the precise mechanism as to how p7 and its ion channel function contributes to virus production is still elusive, recent structural and functional studies have revealed a number of intriguing new facets that should guide future efforts to dissect the role and function of p7 in the viral replication cycle.
    [Show full text]
  • A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
    viruses Communication A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures Ryan P. Bennett 1,† , Courtney L. Finch 2,† , Elena N. Postnikova 2 , Ryan A. Stewart 1, Yingyun Cai 2 , Shuiqing Yu 2 , Janie Liang 2, Julie Dyall 2 , Jason D. Salter 1 , Harold C. Smith 1,* and Jens H. Kuhn 2,* 1 OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; [email protected] (R.P.B.); [email protected] (R.A.S.); [email protected] (J.D.S.) 2 NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA; courtney.fi[email protected] (C.L.F.); [email protected] (E.N.P.); [email protected] (Y.C.); [email protected] (S.Y.); [email protected] (J.L.); [email protected] (J.D.) * Correspondence: [email protected] (H.C.S.); [email protected] (J.H.K.); Tel.: +1-585-697-4351 (H.C.S.); +1-301-631-7245 (J.H.K.) † These authors contributed equally to this work. Abstract: Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody- based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane.
    [Show full text]